Jarero-Basulto, J.J.; Rivera-Cervantes, M.C.; Gasca-Martínez, D.; García-Sierra, F.; Gasca-Martínez, Y.; Beas-Zárate, C.
Current Evidence on the Protective Effects of Recombinant Human Erythropoietin and Its Molecular Variants against Pathological Hallmarks of Alzheimer’s Disease. Pharmaceuticals 2020, 13, 424.
https://doi.org/10.3390/ph13120424
AMA Style
Jarero-Basulto JJ, Rivera-Cervantes MC, Gasca-Martínez D, García-Sierra F, Gasca-Martínez Y, Beas-Zárate C.
Current Evidence on the Protective Effects of Recombinant Human Erythropoietin and Its Molecular Variants against Pathological Hallmarks of Alzheimer’s Disease. Pharmaceuticals. 2020; 13(12):424.
https://doi.org/10.3390/ph13120424
Chicago/Turabian Style
Jarero-Basulto, José J., Martha C. Rivera-Cervantes, Deisy Gasca-Martínez, Francisco García-Sierra, Yadira Gasca-Martínez, and Carlos Beas-Zárate.
2020. "Current Evidence on the Protective Effects of Recombinant Human Erythropoietin and Its Molecular Variants against Pathological Hallmarks of Alzheimer’s Disease" Pharmaceuticals 13, no. 12: 424.
https://doi.org/10.3390/ph13120424
APA Style
Jarero-Basulto, J. J., Rivera-Cervantes, M. C., Gasca-Martínez, D., García-Sierra, F., Gasca-Martínez, Y., & Beas-Zárate, C.
(2020). Current Evidence on the Protective Effects of Recombinant Human Erythropoietin and Its Molecular Variants against Pathological Hallmarks of Alzheimer’s Disease. Pharmaceuticals, 13(12), 424.
https://doi.org/10.3390/ph13120424
